Compare Medpace Holdings Inc (MEDP) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.7. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MEDP | QDTY | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $620.59 | $46.71 |
52-Week Low | $393.42 | $36.57 |
Enterprise Value | $16.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
QDTY trades at $39.75, showing minimal daily movement with a -0.13% decline. The technical picture remains neutral overall with bearish moving averages, while the company demonstrates consistent dividend distributions through its weekly payout structure. Recent YieldMax ETF announcements highlight ongoing distribution activities through mid-2026.
The stock presents income-focused appeal through regular distributions, though fundamental metrics remain unavailable for comprehensive valuation assessment. Key considerations include reliance on ETF distribution strategies and market volatility exposure. The neutral technical stance suggests limited near-term directional momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
